Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 8/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600069 | 1.00 | P2RX7 (0.39) | P2RX7CNR2MAPK1CNR1TRPV1 | |
| SCHEMBL20143007 | 0.91 | CNR2 (0.39) | P2RX7CNR2MAPK1CNR1TRPV1 | |
| SCHEMBL20154267 | 0.91 | CNR2 (0.39) | P2RX7CNR2MAPK1CNR1TRPV1 | |
| SCHEMBL30071194 | 0.91 | CNR2 (0.39) | P2RX7CNR2MAPK1CNR1TRPV1 | |
| SCHEMBL21875829 | 0.90 | CNR2 (0.37) | P2RX7CNR2CNR1BRD4CREBBP | |
| SCHEMBL30824247 | 0.90 | CNR2 (0.37) | P2RX7CNR2CNR1BRD4CREBBP | |
| SCHEMBL21875796 | 0.90 | CNR2 (0.38) | P2RX7CNR2MAPK1CNR1TRPV1 | |
| SCHEMBL29965225 | 0.90 | CNR2 (0.38) | P2RX7CNR2MAPK1CNR1TRPV1 | |
| SCHEMBL20600326 | 0.89 | P2RX7 (0.44) | P2RX7MAPK1TRPV1BRD4CREBBP | |
| SCHEMBL30824208 | 0.89 | P2RX7 (0.44) | P2RX7MAPK1TRPV1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064160-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (US) | 2022-03-03 | — | — | US | claimed |
| CN-110770227-B | Novel azaquinoline derivatives | 拜耳动物保健有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20220064160-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064160-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, PIGS | P2RX7 803/4885CNR2 878/4885MAPK1 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.